secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004734
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine Announces Preclinical Data and 2023 Strategic Priorities at J.P. Morgan Healthcare Conference
--------------------------------------------------------------------------------

- New preclinical data in Friedrich's ataxia and cystic fibrosis show restoration of genetic function via Prime Editing.
- Preliminary off-target safety analyses in Wilson's disease and CGD detected no guide-dependent editing across 170 and 550 sites, respectively.
- PASSIGE technology achieved ~60% precise insertion of a 3.5 kb transgene into primary human T cells in a one-step non-viral process.
- LNP delivery to rodent liver achieved >40% editing of PCSK9 gene and >90% reduction in serum PCSK9 protein.
- Company expects to nominate first development candidate for CGD in Q1 2023 and file first IND as early as 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000119312523004734/0001193125-23-004734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000119312523004734/d448162d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer